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Modulation of peripheral T-cell function by
interleukin-7 in rheumatoid arthritis
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Abstract
Introduction: Interleukin-7 (IL-7) is a cytokine essential for T-cell lymphopoiesis, survival and polarization with an
emerging role in autoimmunity. We previously demonstrated reduced levels of circulating IL-7 in rheumatoid
arthritis (RA), although high amounts are expressed in joints, suggesting differences between systemic and synovial
effects. We observed healthy levels of IL-7 in 48% of RA patients in clinical remission (CR) and aimed to investigate
the consequences of IL-7 deficiency on T-cell responses.
Methods: We used RA patients with active disease and in CR presenting various levels of IL-7, to investigate its
modulatory effects on T cells by analysing responses to phyto-haemagglutinin (PHA), expression of polarization or
survival factors, or suppression by regulatory T cells (Tregs).
Results: IL-7 levels were normal (>10 pg/ml) in 48% of RA patients in CR. Amongst 63 CR patients followed up for
18 months, lack of IL-7 recovery was observed in 13 out of 15 (86%) patients experiencing relapse but only 11 out of
48 (23%) of those who did not (P = 0.0002). Binary regressions showed high significance for below normal IL-7 levels
for self-reported maternal family history of arthritis (odds ratio (OR): 7.66, P = 0.006) and a trend for smoking (OR: 3.33,
P = 0.068) with no further demographic or clinical associations. Serum IL-7 correlated with restored CD4+T-cell response
to PHA (rho = 0.879); this was not related to an increase in T-cell proliferation capacity or expression of survival
factors B-cell lymphoma 2 (BCL2) and BCL2-associated protein X (BAX). Expression of Th1 polarization factor (TBET)
was also dependent on exposure to IL-7 in vivo (rho = 0.600). In contrast CD25highTregs’ response to PHA was
not affected by in vivo IL-7, but their suppression capabilities were related to circulating IL-7 (rho = 0.589).
Co-stimulation with IL-7 (mimicking the joint environment) increased responsiveness of CD4+T-cells to PHA,
lowering the ability of CD25highTregs to suppress them.
Conclusions: Our data demonstrate that IL-7 has a critical role in modulating T-cell function in vivo, possibly
explaining opposing effects observed systemically and in the joint. Lack of IL-7 recovery in CR by maintaining a
suppressed immune system may be a determinant factor in the occurrence of relapse.
Introduction
The exact pathogenesis of rheumatoid arthritis (RA) re-
mains uncertain, but autoimmune processes are clearly
relevant as evidenced by major histocompatibility complex
(MHC) linkage [1,2], auto-antibodies (rheumatoid factor
(RF)) and other antigenic specificities [3]. Lymphocyte in-
filtration into the synovium is an important feature of the
disease. A ‘T-centric’ hypothesis however, presents with a
number of paradigms, notably activated T cells should be
central to this model, but appear predominantly anergic in
the blood of RA patients [4]. Recently, the genetic risk
[5-8] associated with RA has largely implicated T-cell bio-
logical processes, reactivating the interest in this cell type.
Our work on T cells in RA over several years has sug-
gested that particular subsets are lost in RA notably recent
thymic emigrants [9,10] naïve and memory CD4+T cells,
[9] regulatory T cells (Tregs) [11], and compensated by
the presence of abnormal subsets (inflammation related
cells, IRCs) [9]. Some of these abnormalities have been
shown to be associated with relapse following disease-
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modifying anti-rheumatic drug (DMARD)-induced remis-
sion [12], predict safe discontinuation of a therapeutic
anti-tumour necrosis factor (TNF) agent [13] and more
recently predict methotrexate (MTX)-induced remission
in early RA [14] as well as progression towards RA in
anti-citrullinated protein antibody-positive (ACPA+) at
risk individuals (unpublished observation presented at the
European League Against Rheumatism (EULAR) Congress
2013 and the European Workshop for Rheumatology Re-
search (EWRR) 2014). We also associated reduced levels
of interleukin-7 (IL-7) in the bone marrow, thymus and
blood with profound and persistent lymphopenia in RA
post chemotherapy [10,15-17] and showed normalization
of circulating IL-7 levels in approximately 50% of RA pa-
tients in clinical remission (CR) defined by disease activity
score (DAS) <2.6 [12].
Recent studies demonstrated that IL-7 is overex-
pressed in several autoimmune diseases [18,19]. It pri-
marily acts on T cells inducing T helper cell (Th)1- and
Th17-associated cytokine secretion [20,21], dendritic cell
(DC) activation with the production of T-cell differenti-
ating factors, chemokines, adhesion/co-stimulatory mol-
ecules and T-cell-dependent activation of macrophages
(recently reviewed by Bikker and colleagues [22]). IL-7
also coordinates ectopic lymphoid formation [23-25] as
well as T-cell-driven osteoclastogenesis [26,27].
IL-7 is a cytokine of the IL-2 family. It is either secreted
into the circulation or presented in solid tissue by heparan
sulfate and fibronectin on cell surfaces [28]. The IL-7 recep-
tor (IL-7R) is expressed on all circulating CD4+ and CD8+
T cells and natural killer (NK) cells, but not on mature hu-
man B cells. IL-7 has now been associated with the patho-
genesis of RA. Early data showed that IL-7 is expressed at
higher levels in RA synovial tissues than in osteoarthritis
(OA) [15,29] and its expression is related to local inflamma-
tion, measured by either anti-CD68 immunohistochemistry
[29] or by arthroscopic inspection [15,30]. Fibroblasts iso-
lated from RA synovium spontaneously produce IL-7 [31]
in direct relation to their level of exposure to inflammation
in vivo [30] and a significant increase was detected upon
their stimulation with IL-1β or TNF-α. Synovial, but not
blood T cells, respond to IL-7 by spontaneous proliferation
[31,32]. IL-7 stimulation increases the production of TNF-α
by synovial fluid mononuclear cells (SFMCs) and more spe-
cifically of TNF-α and interferon (IFN)-γ by CD4+T cells
[33]. SFMCs pre-incubated (primed) with IL-7 for five days
produced the same effects on CD4+T cells in the absence of
further stimulation with IL-7 [33]. In contrast, we and
others showed that both peripheral blood T cells from RA
patients and healthy controls were unresponsive to IL-7
stimulation alone at physiological concentrations [10,32].
These results suggest possible differences in T-cell func-
tion between the periphery and the joint, where in vivo
levels are respectively low and high [10,17].
This observation prompted us to hypothesize that IL-7
may be responsible for some of the differences in T-cell fea-
tures between active and remitting disease. We had already
demonstrated a direct correlation between in vivo levels of
circulating IL-7 and the functional capacity of the thymus
[10] and showed that peripheral blood mononuclear cells
(PBMCs) from RA patients in CR exhibited increased re-
sponsiveness to phyto-haemagglutinin (PHA) in vitro, in
direct relation to their in vivo exposure to IL-7 [15]. Since
approximately half of RA patients in CR showed restored
normal levels of circulating IL-7 [10], this presented an op-
portunity to evaluate the effect of normal and reduced
in vivo exposure to IL-7 in active and remitting RA.
Using groups of patients either with active RA or in
CR, we observed that the lack of recovery of IL-7 in CR
was associated with relapse in the short term. To explain
this observation, we showed that in vivo exposure to dif-
ferent levels of IL-7 has a profound effect on T-cell re-
sponse to PHA stimulation tested in vitro. This was not
directly related to a change in the proliferative capability
of effector CD4+T cells in reaction to IL-7 or to the ex-
pression of survival factors. Increased expression of the
Th1 (but not Th2) polarization transcription factor was
also observed in relation to IL-7. In contrast to effector
cells, regulatory T-cell proliferation was not affected but
their suppression capabilities were directly related to ex-
posure to IL-7 in vivo.
Methods
Participants
Ethical approval was obtained from the Leeds Teaching
Hospitals NHS Trust Ethics Committee, and informed
consent was obtained from each participant. RA was di-
agnosed using the American College of Rheumatology
(ACR) 1987 criteria. Patients in the early stages of RA
(<2 symptomatic years) were DMARD-naïve (DN) and
divided into those with less than 6 months’ symptom
duration (<6 m DN) (n = 127) and those with 6 to
24 months’ symptom duration (6 to 24 m DN) (n = 37).
Long-lasting RA included DMARD-resistant patients
(n = 55). RA patients in CR (n = 90) were defined using a
clinical DAS28 < 2.6, median 1.6, range 0.64 to 2.58) sus-
tained for at least 6 months; low-grade inflammation de-
fined by C-reactive protein (CRP <10 mg/L, upper limit
of the normal CRP range in the local population). Pa-
tients were on MTX (46%), sulphasalazine (20%), com-
bination of both (23%) or no DMARDs (11%). The term
‘active’ RA refers to all RA patients except those in CR.
Controls included healthy subjects (HC, n = 80) and other
inflammatory disease (active colitis, psoriatic arthritis, anky-
losing spondylitis, gout, reactive arthritis, n = 96) as well as
OA, n = 19. Demographic data can be found in Additional
file 1. There was no significant difference in age range and
gender representation between groups.
Churchman et al. Arthritis Research & Therapy  (2014) 16:511 Page 2 of 13
Measurement of cytokines
All cytokine levels were measured in sera and synovial
fluid (SF) by enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Abingdon, UK), according to
the manufacturer’s instructions. The sensitivity of the
IL-7 assay was 0.1 pg/ml and the range was 0.1 to
24 pg/ml. 1:3 dilution was used for serum and 1:5 for
SF. For other ELISAs (R&D) the ranges for IL-2, IL-6,
IFN-γ, TNF-α and transforming growth factor (TGF)-β1
were 31.2 to 2,000, 3 to 500, 7 to 1,000, 7 to 1,000 and
15 to 3,000 pg/ml, respectively.
Immunohistochemistry and digital imaging scoring
Full details of this method can be found in Additional file 1.
Briefly, slides from paraffin-embedded sections were
dewaxed, washed and stained with mouse monoclonal IL-
7 antibody (R&D Systems, MAB207). Universal probe and
X-Cell Polymer HRP reagents (Menarini Diagnostics,
Wokingham, UK) were applied, followed by 3′-diamino-
benzidine. Slides were counterstained in haematoxylin,
dehydrated by ethanol and mounted in di-n-butyle phthal-
ate xylene. Quantification of IL-7 was performed electron-
ically using 256 shades of DAB with anything above shade
50 considered positive for IL-7.
Phenotypic analysis of T cells and Tregs
T cells and Tregs were phenotyped using naïve and
memory cell surface markers as well as Foxp3 intracellu-
lar staining as previously described [14]. Naïve cells were
defined as CD3+CD4+CD45RBhighCD45RA+CD62L+ and
IRCs as CD3+CD4+CD45RBhigh CD45RA+CD62L− and
Tregs based on CD3+CD4+ and high expression of
CD25 (CD25high) [34], with the addition of Foxp3+ and
CD127low [35,36]. All subsets were quantified as a per-
centage of all CD4+ T cells. Expression of CD127 was re-
corded using mean fluorescence intensity (MFI).
Cell sorting
PBMCs were separated by centrifugation using Lympho-
prep (Axis Shield Diagnostics Ltd, Huntingdon, UK) from
30 ml of heparin blood. Magnetic negative selection of
CD4+T cells was performed as previously described [11].
CD4+T cells were labelled using anti-CD3-FITC (UCHT1,
AbD Serotec, Kidlington, UK), and anti-CD4-PE-Cy5
(MT310, Dako, Ely, UK), anti-CD25-PE (CD25-3G10,
Caltag Laboratories, Burlingame, CA, USA) [11]. CD4+CD25−
and CD4+CD25high fractions were sorted. Both were
assessed for purity using the antibody panel described
above (CD3, CD4, CD25, CD127 and intracellular FoxP3)
and results showed over 95% pure effector T cells or
Tregs.
Proliferation and suppression assays
Total CD4+T cells were negatively selected [11] and resus-
pended (104/well) in RPMI 1640 medium supplemented
with penicillin, streptomycin, glutamine (Invitrogen, Paisley,
UK) and 10% human AB+ serum (Sigma-Aldrich, Poole,
UK). Subsequent assays were performed in 96-well round-
bottomed plates (200 μl/well) in the presence of an equal
number of autologous mitomycin C-treated CD4-depleted
PBMCs as antigen-presenting cells, in response to PHA
(1 μg/ml, Sigma-Aldrich).
Proliferation of sorted CD4+CD25− and CD4+CD25highT
cells was compared following PHA stimulation (2 μg/ml),
with or without the addition of IL-7 (10 ng/ml, R&D Sys-
tems) [11]. The ability of CD4+CD25highTregs to inhibit
CD4+CD25−T-cell proliferation was assessed in four-day
co-culture experiments (1:1 ratio), in the presence of PHA
(2 μg/ml), as previously described [11] with or without the
addition of IL-7 (10 ng/ml).
Real-time PCR quantification of TRECs
T-cell receptor excision circles (TRECs) were quantified
using a real-time PCR-based assay as defined previously
[37] using absolute quantification. DNA was extracted
from each subset using a standard proteinase K diges-
tion and phenol/chloroform extraction. The previous
relative method was used to quantify TREC in total and
naïve CD4 T cells [9,38,39]. TREC molecules were nor-
malized against DNA concentration for cells sorted as
Treg, effector and naïve as the cell number after sorting
was very low.
TREC-F-5′-CACCTCTGGGCTACGTGCTAG-3′,
TREC-R-5′-GAACACATGCTGAGGTTTAAAG
AGAAT -3′.
Real-time PCR analysis of gene expression
RNA was extracted from PBMC and cDNA synthesized,
as described previously [40]. Real-time PCR was per-
formed using an ABI7700 sequence detection system (Ap-
plied Biosystems, Warrington, UK) in the presence of
SYBR Green. Optimization of the real-time PCR reaction
was performed according to the manufacturer’s instruc-
tions. Each gene transcript was normalized to the refer-
ence gene GAPDH. Primer sequences as follows:
GAPDH-F-5′-AACAGGGACACCCACTCCTC-3′,
GAPDH-R-5′-CATACCAGGAAATGAGCTTGACAA-3′,
BCL-2-F-5′-GTGGAGAGCGTCAACCGG-3′
BCL-2-R-5′-GGTTCAGGTACTCAGTCATCCACA-3′,
BAX-F-5′-GCCACTCCTCTGGGACCC-3′
BAX-R-5′-ACGCATTATAGACCACATCTGATG-3′,
T-BET/TBX21-F-5′- TCATTGCCGTGACTGCCTAC-3′,
T-BET/TBX21-R-5′- TGTACATGGACTCAAAGTTC
TCCC-3′,
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GATA3-F-5′- ACTGGAGGACTTCCCCAAGAAC-3′,
GATA3-R-5′-GGCGAGATGTGGCTCAGG-3′
Statistical analysis
Linear variables were not normally distributed amongst
groups of controls or patients; therefore non-parametric
tests were used throughout. Spearman’s rank correlation co-
efficient was used to correlate two variables. Mann-Whitney
U test for two independent samples was used to compare
groups and Kruskal-Wallis for comparisons between more
than two independent samples where appropriate. P values
were adjusted for significance using Dunn’s multiple com-
parison test. IBM SPSS Statistics 21 software was used.
Results
IL-7 levels in disease and controls
Circulating levels of IL-7 have been extensively studied
in HC and active RA [10,15,17] Median IL-7 levels were
14.2 pg/ml in HC (Figure 1A, n = 80, range 7.9 to
30.8 pg/ml with a 95% of values above 10 pg/ml, in agree-
ment with Goëb et al. [17] and a review of 17 manuscripts
incorporating approximately 400 healthy donors [15]) and
7.6 pg/ml in active RA (with >2 years duration, range 1.9
to 10.9 pg/ml) on several DMARD treatment regimes.
Early, DN RA with <6 months symptom duration (<6 m
DN) showed reduced levels of IL-7 (median 12.7 pg/ml,
range 2.8 to 25.1 pg/ml), which reduced even more in 6 to
24 m DN RA (median 7.8 pg/ml, range 2.6 to 17.6 pg/ml).
Serum IL-7 levels are reduced in RA independently of sys-
temic levels of inflammation measured by CRP as previ-
ously demonstrated [10]. OA patients had normal IL-7
(median 13.1 pg/ml, range 9.7 to 19 pg/ml) and patients
with other inflammatory conditions (including active col-
itis, psoriatic arthritis, ankylosing spondylitis, gout, react-
ive arthritis) showed reduced levels only in 14 out of 96
individuals (median 12.7 pg/ml, range 7 to 29.6 pg/ml).
Further data on synovial IL-7 expression are presented in
Figure S1 in Additional file 1.
Serum IL-7 was measured in 90 RA patients in CR (age
range 23 to 79 years) with median remission duration of
18 months (range 6 to 72 months) and median disease dur-
ation of 115 months (range 36 to 300 months). Serum IL-7
Figure 1 IL-7 measures in controls and RA patients. (A) Circulating levels of interleukin (IL)-7 in healthy controls (HC, n = 80), disease-
modifying anti-rheumatic drug (DMARD)-naïve (DN) rheumatoid arthritis (RA) with less than 6 months’ symptom duration (<6 m, n = 127), 6 to
24 months’ symptom duration RA (also DN, 6 to 24 m, n = 37), established long-lasting RA (RA, n = 55), clinical remission (CR, n = 90) osteoarthritis
(OA, n = 19) and other disease controls (n = 96). All RA groups (<6 m DN, 6 to 24 m DN and RA) showed significantly reduced IL-7 levels (all P <0.005)
compared to HC. (B) The ability to recover normal levels of IL-7 in CR was examined with respect to different clinical and demographic parameters.
Lack of IL-7 recovery was significantly associated with patients in CR destined to flare within an 18-month follow-up period (P = 0.072) as well as with
patient self-reported maternal family history of arthritis (P = 0.003). Age at disease onset was directly related to recovered IL-7 levels (rho = 0.539,
P = 0.001). Black triangles are males and open triangles are females.
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levels in CR (Figure 1A) ranged from 2.5 to 22.9 pg/ml
(median 10.7 pg/ml); 48% of patients had normal IL-7
levels (above 10 pg/ml as previously determined) [15,17].
Lack of IL-7 recovery in CR is associated with relapse
Importantly, levels of IL-7 in CR were lower in patients
who experienced a flare within an 18-month follow-up
period (Figure 1B, left panel, P = 0.072). Amongst these
patients, inability to recover healthy levels of IL-7 was
observed in 13 out of 15 (86%) patients experiencing re-
lapse within the follow-up period but only 11 out of 48
(23%) of those who did not (P = 0.0002). Demographic
and clinical data were therefore investigated as to
whether they could predict recovery of healthy levels of
circulating IL-7 in RA patients in CR. Patient age or sex
had no predictive value for recovering healthy IL-7
levels. There was no relationship between IL-7 levels
and the duration of RA before achieving remission or
the duration of remission itself. No relationship was ob-
served between IL-7 and DAS28 score. Other clinical fea-
tures of RA (RF positivity in 42% of patients, shared
epitope in 70%, presence of erosions in 80% and extra-
articular complications in 29%) were not associated with
IL-7 levels in CR. Most patients achieved remission on
therapy, but no association was found with current or past
DMARDs (number or type) or the use of non-steroidal
anti-inflammatory drugs. Extensive imaging was performed
on this cohort and residual synovitis was detected in most
patients either by ultrasound (78% of patients), power Dop-
pler (45%) or magnetic resonance imaging (MRI) (96%)
[12,41], but this revealed no association with IL-7 recovery.
Age at onset of RA influenced IL-7 recovery (Figure 1B
middle panel; rho = 0.539, P = 0.001), suggesting that the
earlier the disease occurred, the lower the likelihood of
having normal levels of IL-7 during CR. Additional in-
formation was obtained related to family history, child
bearing, oral contraception and smoking habits. Patients
reported other cases of inflammatory arthritis (not med-
ically confirmed as RA, but excluding OA) in their fam-
ily only on the maternal side (mother, siblings, maternal
aunt). Levels of IL-7 in this group of patients were
significantly lower (Figure 1B right panel, P = 0.003).
Non-smoking was rarely observed in this cohort (16% of
patients), but was associated with an absence of recovery
of healthy IL-7 levels (P = 0.042). Smoking at the time of
disease onset was also weakly associated with lower
levels of IL-7 (P = 0.063), compared to patients who had
stopped smoking before the onset of RA. No differences
in IL-7 were found between women who had or had not
borne children, taken oral contraception or were post-
menopausal at onset of disease. Binary regression was
used to model IL-7 levels >10 pg/ml. This confirmed
high significance for self-reported maternal family his-
tory of arthritis (OR = 7.66, P = 0.006) and possibly
smoking (OR = 3.33, P = 0.068) with no further demo-
graphic or clinical dependency.
T-cell differentiation and proliferative history
Differentiation of T cells between naïve, memory and Treg
cells was investigated in relation to IL-7 in CR (n = 40).
Naïve cell (CD4+CD45RBhighCD45RA+CD62L+) frequency
was quite variable but no relationship with age was ob-
served as the recovery of thymic activity in CR is inde-
pendent of age although related to levels of IL-7 [10]. In
agreement with these data, naïve cell frequencies were
weakly related to levels of IL-7 (n = 40, rho = 0.400, P =
0.010). In CR patients with normal of IL-7 levels (>10 pg/
ml), the TREC content of naïve CD4+T cells (n = 15, median
6.5%, range 0.9 to 15.6%) was similar to an age-matched
healthy control group (n = 15, median 7.1%, range 2.5 to
17.4%), confirming the absence of proliferation of naïve cells
in remission. In CR patients with below normal levels of IL-
7 (<10 pg/ml), the TREC content of naïve cells remained
low (n = 13, median 2.57%, range 0.41 to 4.57%) suggesting
absence of novel naïve-TREC+ cells being released.
IRCs were lower in remission (median 7.8% range 0.9
to 15.75%) compared to data in active RA (n = 40, me-
dian 10.5%, range 0.7 to 43%, not significant). In the
group defined by healthy levels of IL-7 and associated
with long-term remission, IRCs tended to be lower (me-
dian 3.6%, range 0.9 to 15.4) compared to the group with
low IL-7 and increased risk of flare (median 9.6%, range
3 to 15.75, not significant). The frequency of IRCs was
globally not related to serum IL-7 levels.
We previously showed that the frequency of Tregs
(range 2.12 to 8.32% of total CD4+T cells) in CR was in-
creased compared to active disease [11]. We re-analysed
these data, in relation to serum levels of IL-7 and ob-
served a direct correlation with the frequency of Tregs
(Figure 2A, rho = 0.647, P <0.0001). The TREC content
of the Treg subset was also used to measure the prolifer-
ative history of Tregs and compared to that of the ef-
fector T cells (CD25low) or naïve T cells (CD25− cells).
Flow cytometry strategy is described in Figure 2B. A direct
relationship was confirmed between IL-7 levels and the
TREC content of naïve T cells defined using this alterna-
tive phenotype (Figure 2C left panel, rho = 0.745, P =
0.002). As naïve T cells contain most TREC, this repro-
duced data showing direct relationship between circulat-
ing IL-7 and total CD4+T cell TREC content [10]. The
TREC content of the Treg subset was high (Figure 2C
middle panel, >1,000 molecules/μg DNA) suggesting
absence of proliferation of Tregs. In contrast, the
TREC content of effector T cells was low in all patients
(Figure 2C right panel, <1,000 molecules/μg DNA), as
these predominantly represent activated, effector and
memory T cells, which had previously proliferated, re-
ducing their TREC content.
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Stimulation by PHA
The response of CD4+T cells (negatively separated on
magnetic beads) to PHA stimulation was measured in
relation to serum IL-7 levels. We observed high levels of
proliferation in HC (Figure 3A) compared to DN early
RA patients (P = 0.01). Proliferation in the CR patients
was variable. The in vivo levels of exposure to IL-7 were
positively correlated with the response of CD4+T cells to
PHA stimulation (Figure 3A, rho = 0.879, P <0.0001).
Spontaneous proliferation was negligible and there was
no difference between groups or in relation to IL-7 levels
(data not shown).
We isolated CD4+Tregs (using the same strategy as in
Figure 2B) and effector T cells by cell sorting. Proliferation
of CD4+CD25−T cells in response to PHA was signifi-
cantly higher in controls than in active RA (Figure 3B,
P <0.001) or in CR (P = 0.003). The proliferative capabil-
ities of effector CD4+CD25−T cells in response to PHA
were also directly related to serum levels of IL-7 (Figure 3B,
rho = 0.885, P <0.001). In contrast, CD4+Tregs responded
poorly to PHA alone regardless of clinical group (data not
shown, less than 3,000 CPM).
Co-stimulation with IL-7
Co-stimulation with IL-7 enhances T-cell responses to
stimuli such as PHA, anti-CD3/CD28 or purified protein
derivative [15]. The proliferation assays using effector/Treg
cells were repeated in the presence of IL-7 (10 μg/ml) as
co-stimulator with PHA activation in CR patients. IL-7
alone did not elicit any proliferative response (data not
shown). Effector CD4+T cells showed enhanced prolifera-
tion in response to PHA+ IL-7 (Figure 4A left panel, n = 8,
rho = 0.952, P <0.0001; open symbols) maintaining the rela-
tionship with serum IL-7 levels observed in the absence of
co-stimulation (symbols filled). However, this effect appears
to be much more pronounced in patients with normal
in vivo levels of IL-7 whereas those lacking IL-7 showed
minimum improvement of proliferation. In Tregs, prolifera-
tion was marginally increased by the co-stimulation with
PHA+ IL-7 and the lack of relationship with IL-7 was
maintained (Figure 4A, right panel).
Suppression
We next investigated whether suppression of effector T-
cell proliferation by CD4+Treg (in response to PHA) was
related to in vivo IL-7. Suppressive capacity was signifi-
cantly higher in cells from HC (Figure 4B, left panel)
than those from active RA patients (P <0.05). Suppres-
sion in CR was highly variable and directly related to
serum IL-7 levels (Figure 4B, rho = 0.589, P = 0.006).
Co-stimulation with IL-7 during suppression of effector
T cells by Tregs in vitro was shown to abolish Treg-
Figure 2 IL-7 and Treg proliferative history. (A) CD4+CD25high T regulatory cells (Tregs) were quantified using flow cytometry in peripheral
blood mononuclear cells (PBMCs) from 30 patients in clinical remission (CR) as a proportion of total CD4+ T cells. A direct correlation between the
frequency of CD4+CD25highTregs and serum interleukin (IL)-7 was observed (rho = 0.647, P <0.0001). (B) Flow cytometry strategy T cells (CD25low)
and naïve T cells (CD25− cells). The panel describes further the gating strategy used for cell sorting of naïve cells (bottom 30% of CD25−cells),
effector cells (middle 30% of CD25+cells) and Tregs (top 75% of CD25highcells). (C) T-cell subsets were sorted from 21 CR patients using the gates
described in Figure 2B. DNA was extracted and T-cell receptor excision circle (TREC) content measured by real-time PCR. TREC levels in both naïve
and Treg subsets were high, suggesting a short proliferative history, but lower in the effector subset, indicating several rounds of proliferation.
There was a positive correlation between in vivo IL-7 levels and TREC content of naïve T cells (rho = 0.745, P <0.002).
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suppressive activity [42,43]. The results of the suppression
assay performed in the presence of PHA+ IL-7 were dichot-
omous: in CR patients with low in vivo IL-7, minimal vari-
ation in suppressive activity was observed (Figure 4C). In
contrast, in CR patients with normal serum IL-7, reduction
of suppression was observed in the presence of exogenous
IL-7 (10 to 30% less suppression, indicated by arrows).
Survival
We first examined IL-7R expression using flow cytome-
try on Tregs and T cells (CD127-MFI; Figure S2A in
Additional file 1). We observed minimal difference be-
tween groups (Figure S2B in Additional file 1) suggesting
that changes in T-cell response to IL-7 are unlikely to be
due to difference in levels of receptor expression al-
though expression does vary (by a factor of approxi-
mately 2) at the protein level within each clinical group.
IL-7 has the potential to alter cell survival through the
regulation of BCL2, a key anti-apoptotic protein [44]. To
determine whether improved T-cell responses were related
to changes in the apoptotic signalling balance between
BCL2 and BAX, real-time PCR was used to measure BCL2
and BAX expression in cells from HC, active RA and CR
patients. Expression levels were not significantly different
between any of the three groups (Figure S3 in Additional
file 1, P >0.750 for each comparison).
Furthermore, there was no relationship between BCL2
or BAX expression and serum IL-7 (rho <0.01), suggesting
that differences in IL-7 were not sufficient to alter the bal-
ance of pro- and anti-apoptotic factors and therefore do
not improve response through increased viability of cells.
Relationship of IL-7 with other cytokines
Cytokines often work in a network, their expression
regulating each other. Possible interplay between IL-7
and other cytokines (IL-2, IL-6, IFN-γ, TNF-α, TGF-β1)
was investigated in sera from HC, active RA patients
and CR. Low levels of circulating cytokines were ob-
served in HC (below detection for most individuals),
which significantly differed from levels measured in active
RA (Figure 5A, P <0.05 for all cytokines, data not shown
for IL-2, IL-6 and TGF-β1). In CR, a direct relationship
was observed between IL-7 and IFN-γ (Figure 5A rho =
0.615, P = 0.005). In contrast, all other cytokine levels were
independent of IL-7 (Figure 5A for TNF-α and data not
shown for IL-6 and TGF-β1).
Th1/Th2 polarization
The exact pathogenesis of RA remains unclear, although it
is often referred to as a Th1-driven disease. In relation to
the role of IL-7 in Th1 polarization, the commitment of
cells towards Th1 was further investigated by measuring
Figure 3 Proliferation of T-cell subsets. (A) Proliferation of total CD4+T cells in response to phyto-haemagglutinin (PHA) (2 μg/ml) in healthy
control (HC) (n = 7, circles), active rheumatoid arthritis (RA) (RA, n = 5, diamonds) and in clinical remission (CR) (n = 11, triangles). Significantly
better proliferation was observed in HC compared to active RA (P = 0.01) but not CR. A direct correlation was observed between proliferative
responses of CD4+T cells and in vivo (serum) interleukin (IL)-7 (rho = 0.879, P <0.0001), combining all three groups. (B) Proliferation of effector T
cells (CD4+CD25−) stimulated with PHA (2 μg/ml) in controls (n = 6, circles), active RA (RA, n = 5, diamonds) and CR (n = 8, triangles). Significantly
better proliferation was observed in HC compared to RA (P = 0.003) and with CR (P = 0.001). A direct correlation was observed between serum
IL-7 and effector cell proliferation (rho = 0.885, P <0.0001) combining the three groups.
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their expression of TBET (TBX21) and GATA3, two tran-
scription factors essential for Th1 and Th2 polarization,
respectively [45]. There was no significant difference in ex-
pression of TBET (Figure 5B) but in CR GATA3 expres-
sion was comparable to HC, both being significantly
higher than RA (P <0.020). In CR, a direct relationship
was observed between serum IL-7 and TBET expression
(Figure 5B rho = 0.600, P = 0.011) but not with GATA3.
Discussion
We examined a cohort of RA patients in CR (with low
clinical and biochemical disease activity) in whom the
potentially confounding influence of inflammation was
minimized and compared them with HC and patients
with active RA. A total of 48% of RA patients in CR had
normal in vivo circulating levels of IL-7. Lack of IL-7 re-
covery in CR was associated with increased risk of re-
lapsing and related to familial history of arthritis and
possibly smoking. Serum IL-7 in CR varied from normal
healthy levels to the low levels observed in active RA
[10,15,17]. We confirmed the absence of stimulatory ef-
fect of IL-7 alone on T-cell proliferation [10] as well as
showing the same lack of effect on Tregs. Normal circu-
lating levels of IL-7 were associated with improved T-
effector but not Treg responses to PHA stimulation
across clinical groups. Most importantly, the suppressive
Figure 4 Proliferation and suppression with IL-7 co-stimulation. (A) Proliferation of CD4+CD25− effector T cells (left panel) and CD4+CD25highT
regulatory cells (Tregs) (right panel) in response to phyto-haemagglutinin (PHA) alone (1 μg/ml, closed symbols) and in the presence of interleukin
(IL)-7 (10 ng/ml, open symbols) was measured in eight clinical remission (CR) patients. Dotted arrows indicate changes in proliferative activity. The direct
correlation between effector T-cell proliferation and serum IL-7 (rho = 0.952, P <0.0001) was maintained in the presence of co-stimulation with IL-7
(rho = 0.881, P = 0.004). There was a marginal increase in the proliferation of CD4+CD25highTregs in the presence of IL-7 but proliferation responses
remained very low. (B) CD4+CD25highTreg and CD4+CD25−T cells were co-cultured in the presence of PHA (2 μg/ml). Percentage suppression was
measured in controls (n = 5, circles), active rheumatoid arthritis (RA) (n = 5, diamonds) and CR (n = 8, triangles). Suppression was significantly reduced in
RA (P <0.0001). A direct trend was observed between suppression capabilities and serum IL-7 levels (rho = 0.589, P = 0.006). (C) The suppression assay
was repeated in the presence of IL-7 co-stimulation (10 μg/ml) for the eight patients in CR. Dotted arrows indicate changes in suppression activity.
Suppression was marginally affected in four patients with low IL-7 serum levels (<10 pg/ml) but reduced to a greater degree in patients with normal
serum IL-7 levels.
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capabilities of Tregs were directly related to in vivo ex-
posure to IL-7. In contrast, in vitro co-stimulation with
PHA + IL-7 particularly enhanced the proliferation of ef-
fector T cells with minimal effect on Tregs. Suppression
in the presence of PHA + IL-7 was reduced in CR pa-
tients with normal in vivo levels of IL-7. The extent of
Th1 polarization was also directly related to in vivo ex-
posure to IL-7. None of these effects appear to be medi-
ated by a change in expression of survival factor or the
degree of IL-7R expression on T-cell subsets. We could
not relate any of these findings to previous or current
DMARD usage.
There are several theories regarding the relationship
between circulating IL-7 levels and T cells. According to
one hypothesis, the amount of circulating IL-7 depends
on the rate of its consumption by T cells [46]. This has
been confirmed in conditions including cancer and HIV
infection, but not in RA where lymphodepletion did not
lead to IL-7 accumulation [10]. An alternative hypothesis
suggests that ‘altruism’ could regulate T-cell prolifera-
tion; having satisfied their IL-7 requirement, a number
of T cells would abstain from consuming IL-7 by down-
regulating IL-7R expression [46]. Our data showing no
differences in levels of IL-7R expression on T cells do
Figure 5 Cytokine network and polarization. (A) Circulating levels of tumour necrosis factor (TNF)-α and interferon (IFN)-γ were measured by
enzyme-linked immunosorbent assay (ELISA) in serum from healthy control (HC) (n = 8), active rheumatoid arthritis (RA) (n = 10) and clinical
remission (CR) (n = 20) patients. Levels were mostly below detection in HC (with the exception of two individuals). Increased levels of circulating
cytokines were observed in active RA (P <0.05). In CR, a direct relationship was observed between interleukin (IL)-7 and IFN-γ (rho = 0.615, P = 0.005)
but not with TNF-α. (B) Expression of TBET and GATA3 was measured by real-time PCR in cells from HC (n = 8), active RA (n = 10) in CR (n = 20).
No significant changes were seen in TBET expression, however, GATA3 expression was lower in RA compared to HC (P = 0.0172) and CR (P = 0.0002).
No difference was observed between HC and CR. In CR, a direct relationship was observed between serum IL-7 and TBET expression (rho = 0.600,
P = 0.011) but not with GATA3.
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not support this hypothesis in RA (at least compared to
HC or CR). Further hypotheses explaining the regulation
of circulating IL-7 levels in RA are therefore required. It
is however, established that circulating soluble-IL-7R
(sIL-7R) may have a role [47,48]. Recently, inflammation
was shown to increase sIL-7R expression in systemic
lupus erythematosus and diabetes mellitus type 1 [49].
In multiple sclerosis, aberrant splicing of exon 6 was
shown to increase the production of sIL-7R [50-52] and
that sIL-7R is able to potentiate IL-7 bioactivity and to
promote autoimmunity [53]. We investigated levels of
sIL-7R in 20 CR patients (Figure S4 in Additional file 1)
and showed no direct relationship with levels of IL-7,
suggesting that future work towards understanding the
regulation of circulating IL-7 in RA is still needed.
The lack of IL-7 recovery in CR could indicate low
levels of disease activity (eventually leading to sIL-7R ex-
pression keeping circulating levels low), however we
could not establish any relationship between IL-7 levels
and residual disease activity even when advanced ultra-
sound and MRI techniques were used [10,41,54]. We ob-
served associations with smoking and early disease
onset. Serum IL-7 was identified as a diagnostic marker
in head and neck cancer [55]. Exposure to cigarette
smoke elicited an increase in serum IL-7 in mice lacking
the multidrug resistance genes [56]. Thus, associations
between IL-7 and smoking have been reported but fur-
ther work is needed to understand the mechanisms be-
hind these and our own observations. The strongest
association observed was with a self-reported maternal
family history of arthritis suggesting a genetic link, al-
though recent data provided contradictory evidence with
respect to associations between IL-7R polymorphisms
and RA [57-60].
Our data showing a direct relationship between Treg
frequency and circulating in vivo IL-7 levels are in agree-
ment with previous reports of a similar role in regulating
Treg homeostasis in mice [61]. Contrary to mice, our
data appear to limit this effect to thymic release of new
Tregs in humans rather than through both homeostatic
proliferation and thymic activity. IL-7 signalling through
STAT-5 was also shown to regulate the expression of
Foxp3 in human cells [62,63], which may explain the en-
hanced suppressive capacity of Tregs in relation to IL-7.
In vitro priming of mouse Tregs with IL-7 increased
their suppressive functions [42], which also support our
findings in humans. Co-stimulation with IL-7 also ap-
pears to have effects depending on priming by IL-7,
which may explain the discrepancies in T-cell behaviour
between blood (anergy) and synovium/synovial fluid in
RA (hyper-reactivity) also rendering cells insensitive to
suppression by Tregs.
IL-7 was shown to favour Th1 polarization via a direct
effect on DC [64,65] and T-cell expression of the IL-12R
[66]. The mechanism by which IL-7 polarizes DC into
DC1 is yet to be elucidated [67] but Th1 polarization is
affected in RA [49,68,69] and defects in TBET mRNA
expression were reported [45,70]. Our data therefore
suggest that the deficit in IL-7 in RA may contribute to
the qualitative defect in Th1 polarization. An implication
of IL-7 in Th17 differentiation has recently been pro-
posed in primary Sjögren’s syndrome and in skin cancer
[20,71] although it remained to be explored in RA. An
unstable commitment towards Th1 polarization may
therefore favour the development of Th17 cells [72] and
such bias may result in chronicity.
Further to its direct effect on thymic release of new T
cells and polarization, we found strong correlations be-
tween in vivo exposure to IL-7 in an individual and their
T-cell responsiveness to PHA (and also to TCR or recall
antigen, data not shown) [15] and suppressive capabil-
ities. A missing signal provided by IL-7 could also ex-
plain this effect. IL-7 is a major anti-apoptotic/survival
factor for T cells through its upregulation of BCL-2
[44,73] and T cells deprived of IL-7 die within a few days
[46,74]. Our data suggest that the lack of direct exposure
to IL-7 in vivo was not associated with any detectable ef-
fect on the balance between pro- and anti-apoptotic fac-
tors. Furthermore, patients had normal T-cell numbers
across the range of IL-7 levels (data not shown). It is
therefore unlikely that a deficit in survival signals could
explain our observations on responsiveness and suppres-
sion. The alternative explanation that IL-7 provided a
‘priming’ signal that influences T-cell behaviour remains
the most attractive one [21]. The mechanism of priming,
by which cells maintain long-term memory of a signal
that modifies their behaviour at a later point in time
(that is polarization, transition from naïve to memory),
is not clear; however IL-7 was reported to induce long-
term chromatin remodelling via STAT-5 [75]. It could
be hypothesized that IL-7 exposure causes additional
long-term effects through a similar mechanism.
Conclusions
Altogether, our data suggest that variation in IL-7 levels
may explain circulating T-cell dysfunctions in RA [4,16].
The difference in systemic and joint T-cell behaviours
may also be related to differences in levels of IL-7. Al-
though ethical limitation prevented access to synovial T
cells and collection of SF in CR, we have shown that IL-
7 expression was reduced in synovial tissue biopsies in
relation to local inflammation although these patients
were not in CR (Additional file 1). We have previously
discussed the discrepancy between low systemic IL-7
and high synovial expression in relation to progression
of bone erosion suggesting that reduced systemic IL-7 is
an indicator of active synovitis [17]. Low systemic IL-7
in CR may therefore suggest persistent high joint IL-7,
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despite no indication that circulating IL-7 levels in CR
were linked to residual disease activity detected by quali-
tative imaging technologies. The association between re-
lapse and lack of IL-7 recovery may suggest that the
mechanism controlling IL-7 recovery remains in ‘active
disease mode’ in such patients and that CR may not be
equivalent to immunological remission as much as it does
not equate to imaging remission [41]. In conclusion, our
data reinforce that in humans, the concept of blocking IL-
7 in autoimmunity may have important therapeutic effects,
as recently demonstrated in the collagen-induced arthritis
model [76] as well as in several other autoimmune disease
animal models [77-82] and in melanoma [71]. Two clinical
trials in multiple sclerosis (NCT02045732) and diabetes
mellitus type 1 (NCT02038764) using an antibody that
binds to and inhibits the human IL-7 receptor are actively
recruiting participants.
Additional file
Additional file 1: Method: Immunohistochemistry and digital
imaging scoring. Table S1. Presents the demographic data of the
cohorts studied. Figure S1A. Describes synovial fluid levels of IL-7
measured in RA (n = 32), OA (n = 25) and reactive arthritis (n = 4).
Figure S1B. Presents immunohistochemistry staining for IL-7 expression
in synovial biopsies from RA (n = 25) and OA (n = 5) patients and results
of digital image analysis used to score IL-7 expression. Figure S1C.
Shows correlation of IL-7 expression with arthroscopic VAS. Figure S2A.
Describes IL-7R (CD127) expression on the cell surface of CD4 + T-cell
subsets. Figure S2B. Shows surface expression of IL-7R on T cells and
Tregs in HC (n = 78), early RA (ERA, n = 50), 24 long-lasting RA (RA, n = 24)
and CR (n = 26). Figure S3. Presents expression of BCL2 and BAX
measured by real-time PCR in HC (n = 8), active RA (n = 10) and in CR
(n = 18). Figure S4. Lack of correlation between sIL-7R to IL-7.
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